[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-bleeding":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,39,72,106,134,175,199,229,252,277,301,326,354,381,402,424,453,480,503],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100648994","a-disposable-endoscopic-closing-device-used-for-the-closure-of-gastrointestinal-tissue-100648994",false,"NCT07727564","A Disposable Endoscopic Closing Device Used for the Closure of Gastrointestinal Tissue","A Disposable Endoscopic Closing Device Used for the Closure of Gastrointestinal Tissue: a Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. No restrictions on gender or race.\n2. Intraoperative endoscopic confirmation of gastrointestinal tissue defects or lesions (≤50 mm) requiring closure, such as post-endoscopic resection mucosal defects, gastrointestinal fistulas, active bleeding, gastrointestinal perforation, colonic diverticular bleeding, etc.\n3. The local anatomy, tissue thickness, and inflammatory status of the target lesion and its surrounding tissues are assessed by the endoscopist as sufficient to withstand the mechanical tensile and anchoring forces exerted by the device (screws or clips).\n4. Patients possess good communication skills and compliance, are willing to cooperate in completing a 30-day clinical follow-up observation, and have an expected survival of more than 6 months.\n5. Voluntary participation in this clinical trial, with written informed consent approved by the Ethics Committee signed by the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Presence of severe coagulation disorders, specifically defined as: platelet count \\\u003C 50 × 10⁹\u002FL, or international normalized ratio (INR) \\> 2.0, or partial thromboplastin time (PTT) \\> 2× the upper limit of normal, and not correctable by blood product transfusion or medication prior to the procedure.\n2. Concomitant high-risk conditions such as severe organ dysfunction, including: severe hepatic or renal insufficiency (AST or ALT \\> 3× upper limit of normal; serum creatinine \\> 3× upper limit of normal), heart failure classified as NYHA Class III-IV, or presence of impaired consciousness, or profound hemorrhagic shock (systolic blood pressure \\\u003C 90 mmHg and heart rate \\> 110 bpm) without successful resuscitation.\n3. Continuous use of systemic anticoagulants (e.g., warfarin, novel oral anticoagulants) or dual antiplatelet agents within 7 days prior to the procedure (with the exception of aspirin monotherapy), and inability to safely discontinue or implement bridging therapy before and after the procedure.\n4. Known allergy to medical-grade surgical stainless steel (containing metallic components such as nickel, cobalt, chromium), polypropylene polymeric materials, or anesthetic\u002Fsedative medications required for endoscopic procedures.\n5. Female patients who are pregnant or breastfeeding.\n6. Current participation in another drug or medical device clinical trial, with less than 30 days having elapsed since the last withdrawal from the previous trial, or presence of any other factors that, in the investigator's opinion, may interfere with the evaluation of trial outcomes.\n7. Conditions deemed by the investigator as inappropriate for the patient's enrollment.","ALL",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","This clinical trial employs a prospective, multicenter, randomized, single-blind, parallel-controlled, non-inferiority design with a positive comparator device. The study aims to assess the safety and efficacy of the disposable endoscopic closing device manufactured by Jiangsu Vedkang Medical Science and Technology Co., Ltd. when applied for gastrointestinal tissue closing and hemostasis.\n\nThe trial group will undergo closure and hemostasis using disposable endoscopic closing device.\n\nThe control group will undergo closure and hemostasis using metal clips, or metal clips in combination with nylon loops.\n\nThis device is clinically indicated for patients requiring closure of gastrointestinal tissue.\n\nPrimary effectiveness endpoint: composite clinical success rate. Secondary effectiveness endpoints: endoscopic procedure time. Secondary safety endpoints: incidence of adverse events, incidence of serious adverse events, and incidence of device malfunctions.\n\nVital signs and hemoglobin changes will be closely monitored during the 24-hour period following the procedure. At 7 days postoperatively, a follow-up assessment (either outpatient or by telephone) will be performed. At 30 days postoperatively, the final outpatient follow-up visit will be conducted.",[25,26],"Gastrointestinal Bleeding","Gastrointestinal Neoplasms","NOT_YET_RECRUITING","2026-07-22",{"date":30,"type":31},"2026-07-27","ACTUAL",{"date":33,"type":19},"2026-07-31",{"date":35,"type":19},"2027-07-30",{"name":37,"class":38},"Jiangsu Vedkang Medical Science and Technology Co., Ltd","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100536012","comprehensive-hht-outcomes-registry-of-the-united-states-chorus-100536012","NCT06259292","Comprehensive HHT Outcomes Registry of the United States (CHORUS)","CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States","CHORUS","Inclusion Criteria:\n\n* Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.\n* Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.\n\nExclusion Criteria:\n\n* Unable to provide informed consent or informed consent via a parent or legally authorized representative.",true,{"count":49,"type":19},10000,"10 Years","OBSERVATIONAL","The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease.\n\nAnother important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study.\n\nParticipants will:\n\n* Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information.\n* Be asked study-related questions by phone or at a clinic visit.\n* Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year\u002Fs including new test results, treatment information, symptoms, and complications from HHT.",[54,55,56,57,58,59,60],"Hereditary Hemorrhagic Telangiectasia","Arteriovenous Malformations","Telangiectasia","Epistaxis","GastroIntestinal Bleeding","Cerebral Arteriovenous Malformations","Vascular Malformation","RECRUITING","2026-07-16",{"date":64,"type":31},"2026-07-17",{"date":66,"type":31},"2023-11-13",{"date":68,"type":19},"2033-11",{"name":70,"class":38},"Cure HHT",16,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100646451","phase-3-tegoprazan-for-prevention-of-gastrointestinal-complication-in-ischemic-stroke-patients-on-antiplatelet-therapy-tegostroke-100646451","NCT07687706","Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)","TegoStroke","Inclusion Criteria:\n\n1. Age 19 years or older.\n2. Hospitalization for acute ischemic stroke or transient ischemic attack, with antiplatelet therapy initiated for the first time, expected to continue for at least 6 months at the treating physician's discretion per relevant stroke guidelines, and within 4 weeks of the first antiplatelet dose at the time of randomization.\n3. Written informed consent provided by the participant or a legally authorized representative.\n4. Ability and willingness to understand the study procedures described in the consent form and to comply with the study protocol.\n\nExclusion Criteria:\n\n1. History of peptic ulcer disease diagnosis or gastrointestinal bleeding within the past year. At screening, the history and findings of any EGD performed within the preceding 2 years were obtained by participant interview.\n2. Need for concomitant anticoagulant therapy (transient anticoagulation such as argatroban during the index admission is permitted, with randomization after it is stopped)\n3. Anticipated difficulty in undergoing gastrointestinal endoscopy during the study period.\n4. Use of a P-CAB, PPI, or H2-receptor antagonist within 1 week before randomization, or an active indication for these agents, a mucosal protectant, or an antacid at enrollment. Temporary use of these agents during acute care in the index admission, since discontinued and without a current indication, is not exclusionary.\n5. Hypersensitivity or contraindication to a P-CAB or to benzimidazoles.\n6. AST, ALT, ALP, or γ-GT ≥5 times the upper limit of normal (ULN), or total bilirubin ≥3 times the ULN at screening.\n7. Participation within the past 12 months in any of the following: (1) a clinical study that may affect the efficacy or safety assessments of the present study; (2) a study involving an investigational product or procedure not administered under standard-of-care guidelines; (3) a study that may pose additional risk to the participant. (Participation in other clinical studies is otherwise permitted.)\n8. Current use of, or use within five half-lives of, a contraindicated interacting drug (atazanavir, nelfinavir, rilpivirine, and preparations containing these components).\n9. Any other condition deemed by the investigators to render the patient unsuitable for study participation, including but not limited to:","19 Years",{"count":82,"type":19},1524,[84],"PHASE3","Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke.\n\nTegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for patients on antiplatelet therapy after ischemic stroke.",[87,88,89,90,91,25],"Ischemic Stroke","Ischemic Stroke, Acute","Transient Ischemic Attack (TIA)","Cerebrovascular Disease","Gastrointestinal Complication",[91,93,94,87,95,90],"Gastroprotection","Gastrointestinal Gleeding","Transient Ischemic Attack","2026-07-07",{"date":98,"type":31},"2026-07-08",{"date":100,"type":31},"2026-01-26",{"date":102,"type":19},"2027-12",{"name":104,"class":38},"Hanyang University Guri Hospital",24,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":20,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100628866","phase-3-routine-use-of-potassium-competitive-acid-blocker-vs-guideline-directed-gastrointestinal-protection-strategy-in-acute-myocardial-infarction-100628866","NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial","PCAB-AMI","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).\n* Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.\n\nExclusion Criteria:\n\n* History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \\[P-CAB\\] or proton pump inhibitor \\[PPI\\]).\n* Presence of active gastrointestinal bleeding.\n* Pregnant or breastfeeding women.\n* Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).\n* Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.",{"count":115,"type":19},5000,[84],"This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).",[119,25],"Acute Myocardial Infarction (AMI)",[121,122,123,124],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","Potassium Competitive Acid Blocker","Zastaprazan","2026-06-23",{"date":127,"type":31},"2026-06-26",{"date":125,"type":31},{"date":130,"type":19},"2030-12-31",{"name":132,"class":38},"Samsung Medical Center",1,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":20,"phases":145,"briefSummary":146,"conditions":147,"keywords":159,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":133},"100557838","marginal-ulcer-healing-with-low-thermal-argon-plasma-endoscopic-treatment-100557838","NCT06543316","Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","Accelerated Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","AMULET","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.\n* Subjects must be scheduled for an EGD for the evaluation of these symptoms.\n* Marginal ulcers confirmed during the initial EGD.\n* Willingness to adhere to the SOC treatment, which includes PPIs.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent and understanding of study requirements.\n* Willingness and ability to attend required follow-up assessments at 4 weeks (+\u002F- 1 week) and 8 weeks (+\u002F- 2 weeks).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Inability or unwillingness to comply with the SOC.\n* Current use of systemic antibiotics.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.","18 Years",{"count":144,"type":19},100,[22],"The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.",[148,149,150,151,152,153,154,155,156,58,157,158],"Roux-en-y Anastomosis Site","Marginal Ulcer","Marginal Ulcer (Peptic) or Erosion","Ulcer","Ulcer, Gastric","Ulcer Gastrointestinal","Abdominal Pain","Nausea","Vomiting","Dysphagia","Ulcer Gastrojejunal",[160,161,162,163,164,165,166],"Argon Plasma Coagulation","APC","Low-Thermal Argon Plasma Endoscopic Treatment","Endoscopy","RYGB","Roux-en-Y Gastric Bypass","Ulcer Healing",{"date":168,"type":31},"2026-06-25",{"date":170,"type":31},"2025-03-04",{"date":172,"type":19},"2028-06",{"name":174,"class":38},"Christopher C. Thompson, MD, MSc",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":47,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":133},"100512193","video-capsule-endoscopy-for-detection-of-gastrointestinal-bleeding-in-the-small-bowel-100512193","NCT05949268","Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel","Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Jejunum","Inclusion Criteria:\n\n* suspicion of gastrointestinal bleeding in the small bowel undetected by gastroscopy and colonoscopy\n* informed consent\n\nExclusion Criteria:\n\n* contraindications for small bowel capsule endoscopy (e.g. stenosis)",{"count":183,"type":19},1300,"Small bowel capsule endoscopy is the main diagnostic standard for small bowel bleeding. This study investigates the detection rate of small bowel bleeding in capsule endoscopy and further endoscopic treatment in a prospective and retrospective cohort.",[58],[187,188,189],"Small bowel capsule endoscopy","gastrointestinal bleeding","anticaogulation","2026-04-27",{"date":192,"type":31},"2026-05-01",{"date":194,"type":31},"2023-09-01",{"date":196,"type":19},"2028-07-15",{"name":198,"class":38},"University Hospital Freiburg",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":20,"phases":209,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":133},"100571057","a-study-to-evaluate-the-performance-of-a-wireless-optical-sensor-capsule-in-detection-of-ugib-100571057","NCT06715293","A Study to Evaluate the Performance of a Wireless Optical Sensor Capsule in Detection of UGIB","A Prospective Study to Evaluate the Diagnostic Performance of a Wireless Optical Sensor Capsule in Detection of Upper Gastrointestinal Bleeding","Hemopill-Pro","Inclusion Criteria:\n\n1. Participants have symptoms and signs of suspected UGIB (melena, per rectal bleeding, coffee ground vomiting, prior hematemesis);\n2. Participants will undergo urgent or elective OGD within 24 hours from recruitment;\n3. Written consent obtained.\n\nExclusion Criteria:\n\n1. Contraindications for OGD (e.g. respiratory failure, suspected perforation);\n2. Contraindications for capsule endoscopy (e.g. known gastrointestinal obstruction or stricture, severe dysphagia, impaired consciousness);\n3. Cardiac pacemaker or implanted electromedical devices;\n4. History of gastrectomy or bowel resection;\n5. Ongoing fresh hematemesis requiring emergent endoscopy;\n6. Unstable hemodynamics despite adequate resuscitation requiring emergent endoscopy (i.e. systolic blood pressure \\\u003C100mmHg or pulse rate \\>100 per minute);\n7. Advanced comorbidities (defined as American Society of Anesthesiologists grade 4 or above);\n8. Pregnancy.",{"count":208,"type":19},193,[22],"Upper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB remains high (\\>2%). An accurate risk stratification is necessary to triage patients into low- or high-risk groups, in order to inform clinicians for the necessity and timing of urgent endoscopy. However, existing pre-endoscopy risk scores, such as the Glasgow-Blatchford score (GBS), Rockall score and AIMS65 score, are suboptimal in predicting relevant clinical outcomes. An alternative strategy for risk stratification is urgently warranted in patients with UGIB to guide the next step of management.\n\nIn a pre-clinical study, the sensitivity and specificity of HemoPill® prototype were 95% and 87.5% respectively, when the sensors were positioned close to the bleeding point. Furthermore, several human clinical studies have proven the feasibility and accuracy of HemoPill® in healthy volunteers and patients with suspected UGIB. Capsule ingestion was well tolerated with no device-related adverse event or capsule retention. All patients with negative HI were found to have no active endoscopic bleeding (true negative, 100%, 17\u002F17). In patients with bleeding \\>20ml, true positive HI signals were detected (100%, 2\u002F2) In a retrospective multi-center study, 61 patients with suspected UGIB were recruited to use HemoPill®. Among the capsule-positive cases, subsequent endoscopy confirmed active bleeding in 57% (20\u002F35) of them. None of the capsule-negative patients rebled (0%, 0\u002F25), which prevented unnecessary emergent endoscopy in 72% of them (18\u002F25).",[212,25,213],"Melena","Hematemesis",[215,188,216,217,218,219],"GIB","melena","per rectal bleeding","coffee ground vomiting","hematemesis","2026-04-20",{"date":222,"type":31},"2026-04-22",{"date":224,"type":31},"2025-11-05",{"date":226,"type":19},"2028-04-30",{"name":228,"class":38},"Chinese University of Hong Kong",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100629970","capsule-endoscopy-in-gi-bleeding-a-retrospective-study-100629970","NCT07481591","Capsule Endoscopy in GI Bleeding: A Retrospective Study","Retrospective Analysis of the Diagnostic Value of Capsule Endoscopy in Patients With Gastrointestinal Bleeding","Inclusion Criteria:\n\n* Age ≥18 years old;\n* Obvious symptoms of gastrointestinal bleeding (such as hematemesis, melena, hematochezia, and positive fecal occult blood test);\n* From January 2021 to December 2025, magnetic capsule endoscopy was performed at Chang Hai Hospital\n\nExclusion Criteria:\n\n* Known or suspected intestinal obstruction, stenosis, or fistula;\n* Severe asthma, swallowing disorders, or gastroparesis and other motility disorders;\n* History of abdominal surgery that has affected the normal structure of the digestive tract in the past;\n* When capsule retention occurs, the problem cannot be solved through surgical means due to subjective or objective reasons;\n* Implantable medical devices such as pacemakers, cochlear implants, drug infusion pumps, and nerve stimulators are installed inside the body, except for MRI compatible products;\n* Pregnant women;\n* Patients who need to undergo MRI examination before capsule endoscopy is discharged;\n* Suffering from severe heart and lung diseases (severe myocardial infarction, arrhythmia, heart failure, respiratory failure, etc.);\n* Refusing capsule endoscopy or gastroscopy examination;\n* Researchers believe that there are any other influencing factors that are not suitable for participants to participate in the study",{"count":237,"type":19},350,"The goal of this observational study is to evaluate the diagnostic value and safety of capsule endoscopy in patients with gastrointestinal bleeding. The main questions it aims to answer are:\n\nWhat is the overall detection rate of bleeding lesions using capsule endoscopy? What is the completion rate of capsule endoscopy, and how long does it take for the capsule to pass through the stomach and small intestine? What adverse events (such as capsule retention) occur during or after the procedure?\n\nParticipants who underwent capsule endoscopy for gastrointestinal bleeding at Changhai Hospital between January 2021 and December 2025 will:\n\nHave their existing medical records (including endoscopy reports, procedure notes, and follow-up records) reviewed by researchers Have their personal information anonymized and protected Not be required to undergo any additional tests, procedures, or visits This is a retrospective study that only analyzes previously collected data. No new interventions or patient contact is involved.",[25],[188,241,242],"retrospective study","capsule endoscopy","2026-03-16",{"date":245,"type":31},"2026-03-19",{"date":247,"type":19},"2026-03-15",{"date":249,"type":19},"2026-05-15",{"name":251,"class":38},"Changhai Hospital",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":133},"100568389","utilizing-of-physiological-parameters-predict-the-prognosis-of-cirrhotic-patients-with-gastrointestinal-bleeding-100568389","NCT06680583","Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding","Utilizing of Physiological Parameters And Derived Indices to Predict The Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding","SI","Inclusion Criteria: cirrhosis with gastrointestinal bleeding -\n\nExclusion Criteria: no complete medical record and trauma patient\n\n\\-",{"count":261,"type":19},150,"Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the prognosis of cirrhosis patients with gastrointestinal bleeding? To explore the improvement of emergency and critical care patient management.",[264,25],"Liver Cirrhosis",[266,188,267,268],"cirrhosis","physical indicator","shock index",{"date":270,"type":31},"2026-03-17",{"date":272,"type":31},"2024-11-01",{"date":274,"type":19},"2027-03-11",{"name":276,"class":38},"St. Martin De Porress Hospital",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":20,"phases":286,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":133},"100619079","early-phase-1-yiwei-jiaohuang-ointment-for-gastrointestinal-bleeding-associated-with-oral-antithrombotic-agents-100619079","NCT07339956","Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents","Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Oral therapy with at least one antiplatelet or anticoagulant agent, including: aspirin, clopidogrel, ticagrelor, prasugrel, warfarin, rivaroxaban, apixaban, edoxaban, dabigatran, etc.;\n* BARC stage 1 or 2;\n* Traditional Chinese Medicine pattern identified as phlegm-heat and blood stasis obstruction syndrome;\n* Age 18-90 years;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with gastrointestinal bleeding resulting in hemoglobin levels \\\u003C20 g\u002FL and\u002For requiring hospitalization;\n* Gastrointestinal malignancies;\n* Cases where the source of occult blood cannot be distinguished, such as fresh bleeding from hemorrhoids;\n* Concurrent use of hemostatic traditional Chinese medicine preparations like Yunnan Baiyao;\n* Significant liver or kidney dysfunction, with ALT, AST, or serum creatinine exceeding three times the upper limit of normal;\n* Pregnant women, women planning pregnancy, or lactating women;\n* Individuals deemed unsuitable for this clinical trial by the investigator.","90 Years",{"count":18,"type":19},[287],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the clinical efficacy and safety of YiWei Jiaohuang Ointment in treating gastrointestinal bleeding associated with oral antithrombotic therapy. The main question it aims to answer is:\n\nDoes Yiwei JiaoHuang Ointment accelerate the conversion to negative results in fecal occult blood tests among patients with gastrointestinal bleeding associated with antithrombotic therapy? Researchers will compare use rabeprazole alone as routine therapy to see if Yiwei JiaoHuang Ointment can accelerate the conversion to negative results in fecal occult blood tests.\n\nParticipants will ： Take Yiwei JiaoHuang Ointment every day for 2 weeks. Return to the hospital for a fecal occult blood test after 3 days, 1 week, and 2 weeks of medication.",[25],[291,292],"Antithrombotic therapy","Traditional Chinese Medicine","2026-01-23",{"date":100,"type":31},{"date":296,"type":19},"2026-01-10",{"date":298,"type":19},"2026-08-30",{"name":300,"class":38},"China-Japan Friendship Hospital",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":133},"100618555","management-of-gastrointestinal-bleeding-under-direct-oral-anticoagulants-100618555","NCT07333144","Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants","Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants: Analysis of Reversal Practices Using Prothrombin Complex at the Strasbourg University Hospitals","HEMOD-AOD","Inclusion Criteria:\n\n* Adult patient (≥ 18 years)\n* Male or female\n* Patient admitted to the emergency department for gastrointestinal bleeding (hematemesis, melena, rectal bleeding, or hematochezia)\n* Taking a direct oral anticoagulant (dabigatran, apixaban, or rivaroxaban)\n\nExclusion Criteria:\n\n* Subject who has expressed their objection to the reuse of their data for scientific research purposes.\n* Subject under guardianship, curatorship, or legal protection.",{"count":310,"type":19},250,"Gastrointestinal bleeding (GIB) is a common emergency in hepatology and gastroenterology, with an overall mortality rate ranging from 5% to 10% depending on the study. GIB is classified into two categories: upper GIB (80% of cases) and lower GIB (20% of cases). There are many risk factors for GIB, including anticoagulants. In cases of GD under anticoagulants, there are specific management recommendations. In particular, in cases of severe bleeding under direct oral anticoagulants (DOACs), it is recommended to stop treatment and correct coagulation parameters according to the severity of the bleeding and the associated thrombotic risk. Various treatments can be used for this purpose, including specific antidotes, fresh frozen plasma, and prothrombin complex concentrate (PCC). However, the role of PCC in this indication is uncertain, as is the efficacy and safety data for this drug, due to significant methodological limitations in the few studies conducted on the subject.",[25],[314,315,316],"Gastrointestinal bleeding","Hepatogastroenterology","Direct oral anticoagulants","2025-12-30",{"date":319,"type":31},"2026-01-12",{"date":321,"type":31},"2025-02-28",{"date":323,"type":19},"2026-06-28",{"name":325,"class":38},"University Hospital, Strasbourg, France",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":133},"100618148","how-often-does-the-fecal-test-for-occult-blood-turn-positive-after-using-blood-thinners-100618148","NCT07327853","How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?","Exploring the Prevalence and Potential Benefits of Fecal Immunochemical Test Before Ana After Use of Antiplatelet and Anticoagulant Agents","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Have an indication to use oral antiplatelet or anticoagulant agent(s).\n* Absence of past bleeding tendency of gastrointestinal disease.\n* Agrees to have the test done (FIT).\n* Agrees to sign the informed consent.\n\nExclusion Criteria:\n\n* Presence of past bleeding tendency of gastrointestinal disease.\n* Refusal to have the test done (FIT).\n* Refusal to sign the informed consent.",{"count":334,"type":19},200,"Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover serious disease in the stomach and intestine and enable the treating physician to refer the patient for further evaluation.",[25,337,338],"Antiplatelet Agents","Oral Anticoagulant Therapy",[340,341,314,342,343,344],"Occult fecal blood","Fecal Immunochemical Test (FIT)","Antiplatelet agents","Oral anticoagulant agents","Cardiovascular disease","2025-12-25",{"date":347,"type":31},"2026-01-08",{"date":349,"type":19},"2026-02-01",{"date":351,"type":19},"2027-04-30",{"name":353,"class":38},"Jordan Collaborating Cardiology Group",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":361,"maxAge":142,"enrollmentInfo":362,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":363,"conditions":364,"keywords":370,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":133},"100611388","pediatric-gi-endoscopy-at-assiut-university-100611388","NCT07239934","Pediatric GI Endoscopy at Assiut University","Diagnostic Role of Gastrointestinal Endoscopy in Assiut University Children Hospital","Inclusion Criteria:\n\n* Children aged from 1day to 18 years undergoing diagnostic endoscopy.\n\nExclusion Criteria:\n\n* Incomplete patient data.\n* Patients undergoing follow-up procedures.","1 Day",{"count":261,"type":19},"1. To evaluate the diagnostic role, and outcomes of upper and lower gastrointestinal (GI) endoscopy in identifying gastrointestinal disorders among infants and pediatric patients attending Assiut University Children Hospital.\n2. To determine which pediatric patients require endoscopy as part of the diagnostic process.\n3. To assess the safety and effectiveness of endoscopic procedures in the detection and management of various gastrointestinal disorders among pediatric patients at Assiut University Children Hospital.",[365,366,25,157,367,368,369],"Chronic Diarrhea","Persistent Vomitting","Foreign Body Ingestion","Failure to Thrive","Pediatric Inflammatory Bowel Disease",[371],"pediatric gastrointestinal endoscopy","2025-11-16",{"date":374,"type":31},"2025-11-20",{"date":376,"type":19},"2026-01-01",{"date":378,"type":19},"2027-06-01",{"name":380,"class":38},"Assiut University",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":401},"100413386","validation-of-cagib-score-for-in-hospital-mortality-of-cirrhotic-patients-with-acute-gastrointestinal-bleeding-100413386","NCT04662918","Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding","Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding: A Prospective, International Multicenter, Observational Study","Inclusion Criteria:\n\n1. Patients with liver cirrhosis;\n2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and\u002For hematochezia;\n3. Adults (age≥18 years old).\n\nExclusion Criteria:\n\n1. Components of Child-Pugh, MELD, and CAGIB scores are not available;\n2. In-hospital outcomes are not evaluable.",{"count":389,"type":19},3000,"Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.",[58],"2025-10-02",{"date":394,"type":31},"2025-10-07",{"date":396,"type":31},"2022-01-01",{"date":398,"type":19},"2025-12",{"name":400,"class":38},"Xingshun Qi",23,{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":20,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":423},"100461607","anticoagulation-after-gi-bleeding-pilot-study-and-registry-100461607","NCT05290857","Anticoagulation After GI Bleeding Pilot Study and Registry","Post-Bleed Management of Antithrombotic Therapy After Gastrointestinal Bleeding: Pilot Study and Registry (PANTHER-GI)","PANTHER-GI","Inclusion Criteria:\n\n1. Male or female subjects aged 18 years or older\n2. Hospitalized with acute major non-variceal GI bleeding (defined as per ISTH criteria) while receiving OAC therapy (warfarin or DOAC).\n3. OAC therapy discontinued for current acute GI bleed and not yet resumed\n4. Ongoing indication for long-term anticoagulation of atrial fibrillation (moderate to high risk of stroke\u002Fsystemic embolism with CHA2DS2VASc score of 3 or higher) or VTE (as per clinical care team)\n5. Planned to resume DOAC post-bleed\n6. At moderate to high risk of re-bleeding as per clinical care team\n7. Clinical hemostasis achieved as per clinical care team\n8. Able and willing to comply with follow-up examinations contained within the consent form\n\nExclusion Criteria:\n\n1. Mechanical heart valve\n2. VTE in the context of major transient risk factor and completed 3 months of treatment\n3. GI bleeding managed surgically (e.g. gastrectomy, colectomy)\n4. Active or previously treated gastrointestinal cancer\n5. Life expectancy from other causes of less than 3 months\n6. Platelet count \\\u003C 50,000\u002FµL (or \\\u003C 50x109\u002FL)\n7. Renal dysfunction (Creatine Clearance \\\u003C30 mL\u002Fmin as calculated by the Cockcroft-Gault formula)",{"count":144,"type":19},[22],"PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related gastrointestinal (GI) bleeding among patients at moderate to high risk of re-bleeding and thrombosis. A parallel registry will assess whether eligible patients who are not enrolled in the PANTHER-GI Pilot Study are systematically different than enrolled patients and to explore barriers to enrolment.",[58,414],"Anticoagulant-induced Bleeding","2025-07-28",{"date":417,"type":31},"2025-07-30",{"date":419,"type":31},"2022-03-31",{"date":398,"type":19},{"name":422,"class":38},"Ottawa Hospital Research Institute",2,{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":432,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":20,"phases":435,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":133},"100443924","phase-4-iron-supplementation-in-upper-non-variceal-gastrointestinal-bleeding-100443924","NCT05060731","Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding","Intravenous Ferric Carboxymaltose Versus Oral Ferrous Sulfate Replacement in Anaemia Due to Acute Nonvariceal Gastrointestinal Bleeding (FIERCE): Protocol of a Multicentre Randomised Controlled Trial","FIERCE","Inclusion Criteria:\n\n1. age ≥ 65 years;\n2. endoscopically proven acute nonvariceal GIB source;\n3. 48 hours after the endoscopic diagnosis and\u002For treatment;\n4. hemodynamically stable;\n5. the discharge of the patient is planned;\n6. hemoglobin level \\\u003C10 g\u002Fdl on the day of randomisation;\n7. 24 hours after the last transfusion and no need for further transfusion;\n8. signed informed consent.\n\nExclusion Criteria:\n\n1. known hypersensitivity to iron products (mild side effects excluded);\n2. previous diagnosis of iron overload \\[e.g., transferrin receptor saturation (TSAT) \\>50%, ferritin\\> 160 for women ng\u002Fml, ferritin \\>270 ng\u002Fml for men) or disorders of iron utilisation;\n3. pregnancy or breast feeding;\n4. diagnosis of iron malabsorption (at discretion of the attending clinician; e.g., severe inflammatory bowel disease, active celiac disease);\n5. chronic end stage diseases (chronic heart failure-New York Heart Association Classification class 4, chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2) with or without dialysis, liver cirrhosis with Child Pugh C score, chronic kidney disease with dialysis, chronic obstructive pulmonary disease stage 4, chronic inflammatory disease, malignancies, AIDS);\n6. active malignancies;\n7. liver cirrhosis with known varices at high risk of bleeding - endoscopic features of high risk of variceal bleeding or liver stiffness measured by transient elastography \\>20 kiloPascal and platelet count \\\u003C150 × 10\\^9 cells\u002FL;\n8. gastrointestinal tract malignancies with high risk of gastrointestinal bleeding;\n9. high risk of poor compliance or no fixed abode;\n10. myelo- or lymphoproliferative diseases;\n11. anemia not attributable to iron deficiency (sideroblastic anaemia, aplastic anaemia, haemolytic anaemia, thalassaemia, B12 vitamin or folic acid deficiency or combination of these with IDA);\n12. primary coagulation disorders (e.g. Glanzmann thrombasthenia, Von Willebrand disease, Haemophylia A, Haemophylia B);\n13. the patient will be transferred to another institute after discharge (e.g. hospital, senior care center);\n14. Eastern Cooperative Oncology Group (ECOG) Performance Status \\>2.","65 Years",{"count":434,"type":19},570,[436],"PHASE4","Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation. However, the dose and route of the administration are still a question. The FIERCE clinical trial aims to compare the effect of intravenous iron supplementation and oral iron replacement on mortality, unplanned emergency visits, and hospital readmissions in multimorbid patients with acute nonvariceal gastrointestinal bleeding.",[58,439],"Anemia",[441,442,443],"non-variceal upper gastrointersinal bleeding","iron supplementation","intravenous iron","2025-03-25",{"date":446,"type":31},"2025-03-30",{"date":448,"type":19},"2025-09-01",{"date":450,"type":19},"2028-02-01",{"name":452,"class":38},"University of Pecs",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":20,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":479},"100569794","mce-identifying-bleeding-lesions-in-patients-with-antiplatelet-drugs-related-acute-non-hematochezia-gastrointestinal-bleeding-100569794","NCT06698874","MCE Identifying Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding","Diagnostic Efficacy of Magnetically Controlled Capsule Endoscopy (MCE) for Identification of Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding：Prospective, Multicenter Study","MCE","Inclusion Criteria:\n\n1. No gender limit, age ≥ 18 years；\n2. Acute non-hematochezia gastrointestinal bleeding symptoms, including haematemesis or melena；\n3. Taking antiplatelet drugs continuously for at least 14 days；\n4. Hemodynamically stable；\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years；\n2. Hemodynamically unstable even after initial volume resuscitation and\u002For have ongoing fresh hematemesis at presentation；\n3. With upper gastrointestinal bleeding caused by peptic ulcer or acute gastric mucosal lesion within 1 month before inclusion；\n4. History of endoscopic therapy (such as ESD, EMR, etc.) within 1 month before inclusion；\n5. Gastrointestinal tumor, decompensation of cirrhosis with esophageal or gastric varices；\n6. Haematopathy and bleeding tendency；\n7. Patients who have no surgical conditions or refuse to undergo any abdominal surgery (once the capsule is stuck, it cannot be removed surgically)；\n8. Pacemaker or other implanted electromedical devices which could interfere with magnetic resonance；\n9. Patients plan to undergo magnetic resonance imaging examination before excretion of the capsule；\n10. Suspected or known intestinal stenosis or other known risk factors for capsule retention.\n11. Pregnancy；\n12. Dysphagia；\n13. With and conditon contraindicated to ds-MCE or EGD；\n14. With and conditon that is not suitable for participation in the study evaluated by researchers.",{"count":462,"type":19},204,[22],"The goal of this clinical trial is to explore the diagnostic efficacy of detachable string magnetically controlled capsule endoscopy (ds-MCE) for identification of bleeding lesions in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding. The main questions it aims to answer are:\n\nCompared to the conventional esophagogastroduodenoscopy, does ds-MCE accurately detect bleeding lesions in the upper gastrointestinal tract in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding? Recording bleeding lesions in the small bowel detected by ds-MCE in patients with antiplatelet drugs-related acute non-hematochezia gastrointestinal bleeding.\n\nParticipants will:\n\nUndergo ds-MCE first and subsequently EGD within 24 hours. Receive follow-up in the following 30days.",[25,466],"Antiplatelet Therapy",[468,469,470,188],"magnetically controlled capsule endoscopy","string","antiplatelet drugs","2024-11-20",{"date":473,"type":31},"2024-11-21",{"date":475,"type":19},"2024-12-01",{"date":477,"type":19},"2026-12-30",{"name":251,"class":38},4,{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":133},"100555689","gastrointestinal-bleeding-and-atmospheric-pressure-relationship-100555689","NCT06515353","Gastrointestinal Bleeding and Atmospheric Pressure Relationship","The Effect of Atmospheric Pressure on Patients Presenting to the Emergency Department With Gastrointestinal Bleeding","Inclusion criteria:\n\nPatients aged 18 and above Patients presenting to the emergency department with complaints of gastrointestinal bleeding, whether active or resolved Patients willing to participate in the study Patients from central districts of Ankara\n\nExclusion criteria:\n\nPatients under the age of 18 Pregnant individuals Patients with a history of trauma at the time of admission Patients declaring they are from a city other than Ankara",{"count":310,"type":19},"This study aims to investigate whether atmospheric pressure has an effect on upper gastrointestinal bleeding (UGIB), which includes causes such as peptic ulcer disease, esophagitis, gastritis, gastrointestinal varices, Mallory-Weiss tears, and gastric cancer. The goal is to determine the impact of atmospheric pressure and gather information on its role in high-risk UGIB.",[490,58],"Atmospheric Pressure; Adverse Effect",[492,188,493],"atmospheric pressure","emergency department","2024-07-17",{"date":496,"type":31},"2024-07-23",{"date":498,"type":31},"2024-04-05",{"date":500,"type":19},"2024-11-05",{"name":502,"class":38},"Saglik Bilimleri Universitesi",{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":511,"targetDuration":513,"studyType":51,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":133},"100275283","australian-and-new-zealand-massive-transfusion-registry-100275283","NCT02863250","Australian and New Zealand Massive Transfusion Registry","Improving Outcomes for Patients With Critical Bleeding Requiring Massive Transfusion","ANZ-MTR","Inclusion Criteria:\n\n* aged 18 years or over\n* 5 or more units of red blood cells in any 4 hour period\n\nExclusion Criteria:\n\n* nil",{"count":512,"type":19},50000,"1 Year","Severe and un-stopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include questions regarding how many people have serious bleeding events, what happens to them and the best way to treat them.\n\nThe Massive Transfusion Registry (MTR) is a register of patients who have experienced major blood loss that required a massive transfusion in any clinical setting.\n\nThe MTR uses electronic data extraction and data linkage methodologies. Pre-existing clinical data from hospital data sources, including Laboratory Information Systems (for transfusion history and laboratory results) and Health Information Services databases (for Patient demographics and admission data), are electronically extracted by staff employed at the participating hospitals. The data is then sent to the MTR Research Team, located at Monash University, where it is then linked, analysed and stored.\n\nThe establishment of a Massive Transfusion Registry will be a unique and important resource for clinicians in Australia, New Zealand and internationally, for Blood Services and for the broader community. It will provide valuable observational data regarding the types and frequency of conditions associated with critical bleeding requiring massive transfusion, the use of blood component therapy (i.e. ratios and quantities of different types of red cell to non- red cell components) and patient outcomes.",[516,517,518,25,519,520,521],"Massive Transfusion","Trauma","Cardiothoracic Surgery","Vascular Surgery","Obstetric Bleeding","Liver Transplant","2020-08-31",{"date":524,"type":31},"2020-09-02",{"date":526,"type":4},"2011-03",{"date":528,"type":19},"2028-12-31",{"name":530,"class":38},"Monash University"]